<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34319579</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2190-3948</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery and translational research</Title>
          <ISOAbbreviation>Drug Deliv Transl Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pressure pulsations enhance penetration index in COPD.</ArticleTitle>
        <Pagination>
          <StartPage>1466</StartPage>
          <EndPage>1474</EndPage>
          <MedlinePgn>1466-1474</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13346-021-01027-z</ELocationID>
        <Abstract>
          <AbstractText>This study was done in order to evaluate the effect of a novel pressure pulsation device (Pulsehaler™, Respinova Ltd., Israel) on the deposition pattern of inhaled aerosol in the lungs of COPD patients. Fifteen COPD patients were recruited to undergo spirometry and SPECT-CT lung scan following nebulization of radioactively labeled albuterol in saline solution with a jet nebulizer ("NEB") and with a combined Pulsehaler™/jet nebulizer ("PH + NEB") treatment. Central and peripheral segments of the coronal and transverse SPECT scans were evaluated for total counts and for the ratios between peripheral counts and central counts (penetration Index, "PI"). There was a significant improvement in FEV<sub>1</sub> from before to after albuterol treatment in the PH + NEB group (151 ml ± 187, p &lt; 0.008), but not in the NEB only group (66 ml ± 125, p = 0.06). FVC, FEF<sub>25-75</sub>, FEV<sub>1</sub>%, FVC%, FEF<sub>25</sub>, FEF<sub>50</sub>, and FEF<sub>75</sub> also improved significantly in the PH + NEB group but not the NEB group. There were significant improvements seen between treatments for FEF<sub>25-75</sub> (PH + NEB &gt; NEB, p = 0.0176), FEF<sub>75</sub> (PH + NEB &gt; NEB, p = 0.0028), but not for the other spirometry measures. Borg scores also were improved significantly improved in PH + NEB vs NEB (p = 0.0006). Total lung deposition and total body deposition were lower in the PH + NEB treatments vs the NEB treatments. However, PI values were 3.08 ± 0.67 times greater on average with the PH + NEB (p = 0.026) as compared to NEB only. The magnitude of the increased penetration index observed in this study indicates that pressure pulsations should be further explored as means to improve drug delivery into the distal small airways of the bronchial tree. Effects of the pressure pulsations on small airway patency could be the mechanism by which the effect was achieved.</AbstractText>
          <CopyrightInformation>© 2021. Controlled Release Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gavriely</LastName>
            <ForeName>Noam</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, IIT Haifa, 33095, Technion, Israel. noam@karmelmedical.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Respinova Ltd, Herzliya, Israel. noam@karmelmedical.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>, Tirat Carmel, Israel. noam@karmelmedical.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Volkov</LastName>
            <ForeName>Olga</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Pulmonary Institute, Assaf HaRofeh Medical Center, Zerifin, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fink</LastName>
            <ForeName>Gershon</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Pulmonary Institute, Kaplan Medical Center, Rehovot, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shpirer</LastName>
            <ForeName>Isaac</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Pulmonary Institute, Assaf HaRofeh Medical Center, Zerifin, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Golan</LastName>
            <ForeName>Haim</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Nuclear Medicine Institute, Assaf HaRofeh Medical Center, Zerifin, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Drug Deliv Transl Res</MedlineTA>
        <NlmUniqueID>101540061</NlmUniqueID>
        <ISSNLinking>2190-393X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>QF8SVZ843E</RegistryNumber>
          <NameOfSubstance UI="D000420">Albuterol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000336" MajorTopicYN="N">Aerosols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000420" MajorTopicYN="N">Albuterol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009330" MajorTopicYN="Y">Nebulizers and Vaporizers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D029424" MajorTopicYN="Y">Pulmonary Disease, Chronic Obstructive</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COPD</Keyword>
        <Keyword MajorTopicYN="N">Drug delivery</Keyword>
        <Keyword MajorTopicYN="N">Penetration index</Keyword>
        <Keyword MajorTopicYN="N">Pressure pulses</Keyword>
        <Keyword MajorTopicYN="N">Small airways</Keyword>
        <Keyword MajorTopicYN="N">Terminal bronchioles</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>12</Hour>
          <Minute>56</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34319579</ArticleId>
        <ArticleId IdType="doi">10.1007/s13346-021-01027-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s13346-021-01027-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fridlender ZG, Arish N, Laxer U, Berkman N, Leibovitz A, Fink G, Breuer R. Randomized controlled crossover trial of a new oscillatory device as add-on therapy for COPD. COPD. 2012;9(6):603–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/15412555.2012.748625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilman B. Aerosol deposition and delivery of therapeutic aerosols. Asthma J. 1991;28(4):239–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/02770909109073379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng YS. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech. 2014;15(3):630–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12249-014-0092-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration. 2012;84(2):89–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000341382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gjevre JA, Hurst TS, Taylor-Gjevre RM, Cockcroft DW. The American Thoracic Society’s spirometric criteria alone is inadequate in asthma diagnosis. Can Respir J. 2006;13(8):433–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2006/198940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walenga RL, Longest PW. Current inhalers deliver very small doses to the lower tracheobronchial airways: assessment of healthy and constricted lungs. Pharm Sci. 2016;105(1):147–59. https://doi.org/10.1016/j.xphs.2015.11.027 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xphs.2015.11.027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papandrinopoulou D, Tzouda V, Tsoukalas G. Lung compliance and chronic obstructive pulmonary disease. Pulmonary Medicine. 2012. https://doi.org/10.1155/2012/542769 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/542769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silveira CM, Castiglioni MLV, Torres ICG, Medeiros RB, Jardim JR. Evaluation of two 99mTc-DTPA radioaerosols with different characteristics in lung ventilation studies. Braz J Med Biol Res. 2006;36(10):1333–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S0100-879X2003001000009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleming J, Bailey DL, Chan HK, Conway J, Kuehl PJ, Laube BL, Newman S. Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products. J Aerosol Medpulm D. 2012;25(Supplement):1.</Citation>
        </Reference>
        <Reference>
          <Citation>Phipps PR, Gonda I, Bailey DL, Borham P, Bautovich G, Anderson SD. Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis. 1989;139(6):1516–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/ajrccm/139.6.1516</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
